The Swiss Biotech Association and Parexel join forces to address major clinical trial strategy challenges, including the growing complexity of trials, changing regulations, spiraling costs, and patient access. The meeting will explore the impact of real world data science, adaptive clinical trial design, biomarkers and more.
Join us to hear from top experts from throughout the world and share your knowledge and experience.
Confirmed talks include:
Matthias Grossmann, VP, Parexel Early Phase Scientific Affairs
The fast lane to proof of concept
Dr. Olaf Ritzler, Director, Rare Diseases External Innovation, Sanofi
From No to Yes: What are licensing partners looking for?
Dr. Andrew Galazka, MD, Senior VP, Head of Global Medical Excellence at Merck
Clinical development strategies: lessons learnt and implications for the future
Pantelis Vlachos, Principal Strategic Consultant, Cytel Inc
Adaptive designs: Statistical, operational and regulatory issues
Dr. Justin Devine, Chief Medical Officer, Synexa Group Life Sciences
Using biomarkers to improve the quality of decision making in drug development
Claudia Graeve, VP, Health Advances
Real world data science and the future of clinical trial design
Dr. Victor Cheng, Vice President, Technical, Parexel China
The China opportunity: Considerations for clinical strategy
Swiss Biotech Insight event series - Optimizing the drug development cycle every step of the way